These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27306881)

  • 1. Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy.
    Vitale G; Dicitore A; Messina E; Sciammarella C; Faggiano A; Colao A
    Recent Pat Anticancer Drug Discov; 2016; 11(3):275-82. PubMed ID: 27306881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic regulation of RET receptor tyrosine kinase and non-coding RNAs in MTC.
    Joo LJS; Zhao JT; Gild ML; Glover AR; Sidhu SB
    Mol Cell Endocrinol; 2018 Jul; 469():48-53. PubMed ID: 28315378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAS proto-oncogene in medullary thyroid carcinoma.
    Moura MM; Cavaco BM; Leite V
    Endocr Relat Cancer; 2015 Oct; 22(5):R235-52. PubMed ID: 26285815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on Targeted Therapy in Medullary Thyroid Cancer.
    Okafor C; Hogan J; Raygada M; Thomas BJ; Akshintala S; Glod JW; Del Rivero J
    Front Endocrinol (Lausanne); 2021; 12():708949. PubMed ID: 34489865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
    Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
    JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New drugs for medullary thyroid cancer: new promises?
    Spitzweg C; Morris JC; Bible KC
    Endocr Relat Cancer; 2016 Jun; 23(6):R287-97. PubMed ID: 27185870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
    Dadu R; Hu MN; Grubbs EG; Gagel RF
    Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives.
    Ceolin L; Duval MADS; Benini AF; Ferreira CV; Maia AL
    Endocr Relat Cancer; 2019 Aug; 26(9):R499-R518. PubMed ID: 31252403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in
    Mancikova V; Montero-Conde C; Perales-Paton J; Fernandez A; Santacana M; Jodkowska K; Inglada-Pérez L; Castelblanco E; Borrego S; Encinas M; Matias-Guiu X; Fraga M; Robledo M
    Clin Cancer Res; 2017 Mar; 23(5):1334-1345. PubMed ID: 27620278
    [No Abstract]   [Full Text] [Related]  

  • 10. Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.
    Chu YH; Lloyd RV
    Endocr Pathol; 2016 Dec; 27(4):312-324. PubMed ID: 27539727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.
    Jung CK; Agarwal S; Hang JF; Lim DJ; Bychkov A; Mete O
    Endocr Pathol; 2023 Mar; 34(1):1-22. PubMed ID: 36890425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker identification of medullary thyroid carcinoma from gene expression profiles considering without-treatment and with-treatment studies-A bioinformatics approach.
    Loganathan T; George Priya Doss C
    Adv Protein Chem Struct Biol; 2024; 142():367-396. PubMed ID: 39059991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells.
    Bertazza L; Barollo S; Radu CM; Cavedon E; Simioni P; Faggian D; Plebani M; Pelizzo MR; Rubin B; Boscaro M; Pezzani R; Mian C
    J Cell Mol Med; 2015 Sep; 19(9):2244-52. PubMed ID: 26081844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both
    Demir Gündoğan B; Sağcan F; Tuğ Bozdoğan S; Balcı Y; Tuncel Daloğlu F; Çağlar Çıtak E
    J Clin Res Pediatr Endocrinol; 2021 Aug; 13(3):342-346. PubMed ID: 32702947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
    Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F
    Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Contemporary Review of the Treatment of Medullary Thyroid Carcinoma in the Era of New Drug Therapies.
    Seib CD; Beck TC; Kebebew E
    Surg Oncol Clin N Am; 2023 Apr; 32(2):233-250. PubMed ID: 36925182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathology of C Cells and Medullary Thyroid Carcinoma.
    Schmid KW
    Recent Results Cancer Res; 2015; 204():41-60. PubMed ID: 26494383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [
    Wang Y; Du LL; Hou SH; Han CZ; Zhao XW; Wang WG; Xu XQ; Jing JX
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Nov; 51(11):873-876. PubMed ID: 27938622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sporadic minute medullary thyroid carcinoma with a double RET mutation: A case report.
    Yamamoto H; Ishii J; Chiba T; Nakazato Y; Hirano K; Kamma H
    Pathol Int; 2017 Nov; 67(11):580-584. PubMed ID: 28952196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salinomycin and its derivatives as potent RET transcriptional inhibitors for the treatment of medullary thyroid carcinoma.
    Alqahtani T; Kumarasamy VM; Huczyński A; Sun D
    Int J Oncol; 2020 Jan; 56(1):348-358. PubMed ID: 31746350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.